Peter Dolan

As the former CEO and Chairman of Bristol-Myers Squibb, Mr. Dolan has an impressive track record of leadership in the pharmaceutical industry. His 18 transformative years at BMS included the addition of Eliquis to its portfolio, investment in ImClone’s Erbitux, licensing of Yervoy, and substantial investments in biologics.

Post-BMS, Mr. Dolan led GeminX to a $225 million acquisition by Cephalon Pharmaceuticals. He served as Chairman of the Board of Trustees at Tufts University and chairs the Partnership for A Healthier America. He holds a BA magna cum laude from Tufts University and an MBA from Dartmouth’s Tuck School of Business.